EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase III)Vergleichsstudie

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

Laurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, Flavio Caprioli, Geert D'Haens, Marc Ferrante, Stefan Schreiber, Raja Atreya, Silvio Danese, James O Lindsay, Peter Bossuyt, Britta Siegmund und 14 weitere

New England Journal of Medicine · 18.07.2024 · 391 (3) · 213-223

DOI: 10.1056/nejmoa2314585 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 18.07.2024. Verfasst von Laurent Peyrin-Biroulet und 25 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Gastroenterology, INFINY Institute, INSERM NGERE, Centre Hospitalier Régional Universitaire de Nancy, Vandœuvre-lès-Nancy, Fra…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Crohn Disease, Ustekinumab. Die Arbeit wurde bisher 215-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCrohn DiseaseUstekinumabAdultFemaleHumansMaleMiddle AgedYoung AdultIntention to Treat AnalysisRemission InductionSeverity of Illness IndexEndoscopy, Gastrointestinal

Substanzen

Antibodies, MonoclonalrisankizumabUstekinumab

Autor:innen und Institutionen

  • From the Department of Gastroenterology, INFINY Institute, INSERM NGERE, Centre Hospitalier Régional Universitaire de Nancy, Vandœuvre-lès-Nancy, France (L.P.-B.); the Division of Gastroenterology and Hepatology, McGill…

Förderung

  • AbbVie

Zitieren

APA

Peyrin-Biroulet, L., Chapman, J. C., Colombel, J. F., Caprioli, F., D'Haens, G., Ferrante, M., Schreiber, S., Atreya, R., Danese, S., Lindsay, J. O., Bossuyt, P., Siegmund, B., Irving, P. M., Panaccione, R., Cao, Q., Neimark, E., Wallace, K., Anschutz, T., Kligys, K., …, & SEQUENCE Study Group (2024). Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease. New England Journal of Medicine, 391(3), 213-223. https://doi.org/10.1056/nejmoa2314585

Vancouver

Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease. New England Journal of Medicine. 2024;391(3):213-223. doi:10.1056/nejmoa2314585

BibTeX
@article{PeyrinBiroulet2024,
  author = {Peyrin-Biroulet, Laurent and Chapman, J Casey and Colombel, Jean-Frederic and Caprioli, Flavio and D'Haens, Geert and Ferrante, Marc and Schreiber, Stefan and Atreya, Raja and Danese, Silvio and Lindsay, James O and Bossuyt, Peter and Siegmund, Britta and Irving, Peter M and Panaccione, Remo and Cao, Qian and Neimark, Ezequiel and Wallace, Kori and Anschutz, Toni and Kligys, Kristina and Duan, W Rachel and Pivorunas, Valerie and Huang, Xiu and Berg, Sofie and Shu, Lei and Dubinsky, Marla and SEQUENCE Study Group, SEQUENCE Study Group},
  title = {Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {3},
  pages = {213--223},
  doi = {10.1056/nejmoa2314585}
}
Kostenlos starten →